CRVS · Corvus Pharmaceuticals, Inc. · Executive Compensation
$10.52
-0.02 (-0.19%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$886.63M
Shares
84.12M
Volume · Oct 28
910.14K
Avg daily vol (3M)
996.23K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Ian T. Clark | board of directors | Resigned | 2026-07-22 |
| Scott Morrison | Board | Resigned | 2026-04-23 |
| Andrew C. Chan, M.D., Ph.D. | Class II director | Appointed | 2026-04-23 |
| David Moore | Class III director | Appointed | 2025-10-02 |
| Richard van den Broek | Class II director | Appointed | 2025-04-09 |
Leadership
- Richard Miller CEO, Board Member
- Leiv Lea CFO
- Andrew C. Chan, M.D., Ph.D. Board Member
- David Moore Board Member
- Edith P. Mitchell, M.D. Board Member
- Linda S. Grais Board Member
- Peter Thompson Board Member
- Richard van den Broek Board Member
- Steve E. Krognes Board Member
Key facts
CIK
1626971
CUSIP
221015100
13F (30d)
21 filings
21 filers
Visit website
Investor relations